DESONIDE
Clinical safety rating: safe
Animal studies have demonstrated safety
Desonide is a synthetic corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory mediators like cytokines, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Desonide is metabolized primarily in the liver via ester hydrolysis to inactive metabolites. Minimal cytochrome P450 involvement. |
| Excretion | Renal (approximately 75% as metabolites, <10% unchanged); biliary/fecal (25%) |
| Half-life | Terminal elimination half-life is 2-3 hours in adults, consistent with short glucocorticoid activity; prolonged in hepatic impairment. |
| Protein binding | ~90% bound to albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | Approximately 0.5 L/kg, indicating distribution into total body water. |
| Bioavailability | Topical: unknown due to variable percutaneous absorption (approx. 1-5% of dose depending on skin condition); not formulated for oral systemic use; no IV formulation. |
| Onset of Action | Topical: 1-2 hours for vasoconstriction; oral (systemic): 2-4 hours for adrenal suppression; not available IV. |
| Duration of Action | Topical: 12-24 hours with once-daily application; systemic effects last 12-36 hours; duration shorter than betamethasone due to lower potency. |
Topical: Apply a thin film to affected area 2-3 times daily; maximum 2 weeks of continuous therapy. Intralesional: Not applicable for desonide. Ophthalmic: Not indicated.
| Dosage form | LOTION |
| Renal impairment | No dose adjustment required for topical use. Systemic exposure is minimal. |
| Liver impairment | No dose adjustment required for topical use. Systemic exposure is minimal. |
| Pediatric use | Topical: Apply a thin film to affected area 1-2 times daily for up to 2 weeks. Use lowest potency and shortest duration due to increased systemic absorption risk. Avoid occlusion. |
| Geriatric use | Use with caution due to thinner skin and increased systemic absorption risk. Apply sparingly to limited areas, avoid prolonged use. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Systemic absorption can occur with extensive use.
| Breastfeeding | It is unknown if desonide is excreted in human milk. Topical use results in negligible systemic absorption; therefore, risk to nursing infant is low. M/P ratio not available. Use caution; avoid application to breast area. |
| Teratogenic Risk | Desonide is a corticosteroid; systemic absorption is minimal with topical use. Animal studies have shown teratogenic effects with high systemic doses. In humans, no adequate studies exist. First trimester: unlikely significant risk with topical use. Second and third trimesters: minimal risk but avoid chronic high-dose application. Use only if clearly needed. |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | Skin atrophy |
| Serious Effects |
["Hypersensitivity to desonide or any component of the formulation.","Untreated bacterial, fungal, or viral skin infections (e.g., herpes simplex, vaccinia, varicella).","Perioral dermatitis","Rosacea"]
| Precautions | ["Topical corticosteroids may cause reversible HPA axis suppression, especially with prolonged use or large body surface area application.","Potential for local adverse effects including skin atrophy, striae, telangiectasias, and secondary infections.","Systemic absorption may lead to Cushing's syndrome, hyperglycemia, and glucosuria.","Use with caution in pediatric patients due to increased susceptibility to HPA suppression.","Avoid occlusive dressings unless directed."] |
Loading safety data…
| Fetal Monitoring | Monitor for maternal skin thinning or adrenal suppression if used extensively. No specific fetal monitoring required; assess fetal growth if used chronically over large areas. |
| Fertility Effects | No studies on fertility effects in humans. Animal studies at high systemic doses showed impaired fertility; topical use is unlikely to cause effects. |